


Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

| | | |
|--|--|---|
|  2144 Accredited to ISO/IEC 17025:2005 | Synlab Laboratory Services Ltd | |
| | Issue No: 040 Issue date: 28 August 2019 | |
| | Gavenny Court Brecon Road Abergavenny Monmouthshire NP7 7RX | Contact: Quality Manager Tel: +44 (0)1873 856688 Fax: +44 (0)1873 858984 E-Mail: labservices.info@synlabuk.com |

Testing performed by the Organisation at the locations specified below

Locations covered by the organisation and their relevant activities

Laboratory locations:

| Location details | Activity | Location code |
|---|---|--|
| Address Gavenny Court Brecon Road Abergavenny Monmouthshire NP7 7RX | Local contact Quality Manager Tel: +44 (0)1873 856688 Fax: +44 (0)1873 858984 Email: labservices.info@synlabuk.com | Drugs of abuse analysis Quality Management A |

Site activities performed away from the locations listed above:

| Location details | Activity | Location code |
|---------------------------------|---|---|
| Commercial premises, Offices | Local contact Quality Manager Tel: +44 (0)1873 856688 Fax: +44 (0)1873 858984 Email: labservices.info@synlabuk.com | Specimen collection (Saliva, Urine) B |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

DETAIL OF ACCREDITATION

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|---------------------------|---|--|---------------|
| BODY FLUIDS | <u>Forensic Testing</u> | The organisation has demonstrated adherence to the relevant requirements of Forensic Science Regulators Code of Practice and Conduct in relation to their Forensic activity. | A |
| Whole Blood (preserved) | Detection and quantification of drugs in relation to S5A of the Road Traffic Act 1988 (as amended) and the Drug Driving (Specified Limits) (England and Wales) Regulations 2014: <u>(Limit) and (Calibration Range):</u> Amphetamine (250µg/l);(50-1000µg/L) Clonazepam (50µg/l); (20-200 µg/L) Diazepam (550µg/l); (100-2000 µg/L) Ketamine (20µg/l); (5-100 µg/L) Lorazepam (100µg/l); (10-200 µg/L) Methadone (500µg/l); (100-1000 µg/L) Methamphetamine (10µg/l); (5-100 µg/L) Methylenedioxymethamphetamine (MDMA) (10µg/l); (5-100 µg/L) 6-monoacetylmorphine(5µg/l); (2.5-50 µg/L) Morphine(80µg/l); (10-200 µg/L) Oxazepam (300µg/l); (50-1000 µg/L) Temazepam (1000µg/l); (100-2000 µg/L) Benzoylcegonine (50µg/l); (10-500µg/L) Cocaine(10µg/l); (5-100 µg/L) | Documented in-house Methods Method 12.0322 using LC-MS-MS | A |
| | Delta-9-tetrahydrocannabinol (2µg/l); (1.0-20 µg/L) | Method 12.03210 using liquid extraction and LC-MS-MS | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|--|--|--|---------------|
| BODY FLUIDS AND PLASMA | <u>Forensic Testing</u> | The organisation has demonstrated adherence to the relevant requirements of Forensic Science Regulators Code of Practice and Conduct in relation to their Forensic activity. | |
| Whole Blood (preserved) | Quantitative analysis of the following drugs (concentration range): Nordiazepam (10-200 µg/L) Norketamine (10-100 µg/L) | Method 12.0322 using LC-MS-MS | A |
| KEDTA Plasma from Blood | Confirmation and Quantitation of: Clozapine Norclozapine | Method 12.03510 using protein precipitation and LC-MS-MS | A |
| | <u>Workplace Drug Analysis/Medical Legal Analysis</u> | Documented In-house Method | |
| Oral fluid extracted from Quantisal collection kit | Presumptive screening for the presence of the following drugs or drug groups (cut-off limits) Amphetamines (40ng/ml) Benzoylcegonine (20ng/ml) Cannabis (4ng/ml) Barbiturates, Benzodiazepines (10ng/ml) Opiates (40ng/ml) Methadone (20ng/ml) | Screening method using CEDIA immunoassay Method 9.0135 Method 9.0130 Method 9.0128 Method 9.0131 Method 9.0132 Method 9.0129 Method 9.0133 | A |
| Urine (unpreserved) | Presumptive Screening for Alcohol (10.1-498mg/100mL); (10-300mg/100mL) | Screening method using DRI assay Method 9. 0108 | A |
| Urine (unpreserved) | Adulteration tests: Creatinine (0.3-50mmol/L) pH Specific Gravity | Method 9.0117 using colourimetry Method 9.0116 using colourimetry Method 9.0119 using colourimetry | A |
| | Ethyl glucuronide (ethanol indicator and not as marker for alcohol abuse) (500ng/ml) | Method 9.0124 using DRI Immunoassay | A |



2144
Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd
Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|---------------------------------|--|---|---------------|
| BODY FLUIDS AND PLASMA (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-house Method | |
| Urine (unpreserved) (cont'd) | Presumptive screening for the presence of the following drugs or drug groups (cut-off limits): Amphetamines (300ng/ml; 500ng/ml; 1000ng/ml) Barbiturates 200ng/ml; 300ng/ml) Benzodiazepines (200ng/ml; 300ng/ml) Benzoyllecgonine (300ng/ml; 150ng/ml) Buprenorphine (5ng/ml) Cannabis metabolites (20ng/ml; 25ng/ml; 50ng/ml) 6 Mono acetyl morphine (10ng/ml) Propoxyphene (300ng/ml) Phencyclidine (PCP) (25ng/ml) Opiates (300ng/ml; 2000ng/ml) Methadone (300ng/ml) Methaqualone (300ng/ml) | using CEDIA Immunoassay Method 9.0103 Method 9.0104 Method 9.0105 Method 9.0106 Method 9.0113 Method 9.0102 Method 9.0114 Method 9.0110 Method 9.0111 Method 9.0107 Method 9.0109 Method 9.0112 | A |
| | Ketamine (500ng/ml; 1000ng/ml) | Method 9.0125 DRI Immunoassay | A |
| | Tramadol (300ng/ml) | Method 9.0126 using Immunoassay | A |
| Urine (unpreserved) | Presumptive screening for the presence of the following drugs (cut-off limits) Amphetamines; Amphetamine (300ng/ml; 500ng/ml; 1000ng/ml) MDMA (300ng/ml; 500ng/ml; 1000ng/ml) MDEA (300ng/ml; 500ng/ml; 1000ng/ml) Methamphetamine (300ng/ml; 500ng/ml; 1000ng/ml) | Method 9.01574 using AB Sciex Triple TOF with fast chromatography | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|---------------------------------|---|---|---------------|
| BODY FLUIDS AND PLASMA (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-house Method | |
| Urine (unpreserved) (cont'd) | <p>Presumptive screening for the presence of the following drugs (cut-off limits) (cont'd):</p> <p>Barbiturates; Phenobarbital (200ng/ml; 300ng/ml) Secobarbital (200ng/ml; 300ng/ml)</p> <p>Benzodiazepines; Aminonitrazepam (200ng/ml; 300ng/ml) Aminoflunitrazepam (20ng/ml; 300ng/ml) Flunitrazepam (20ng/ml; 300ng/ml) Hydroxyalprazolam (200ng/ml; 300ng/ml) Lorazepam (200ng/ml; 300ng/ml) Nordiazepam (200ng/ml; 300ng/ml) Oxazepam (200ng/ml; 300ng/ml) Phenazepam (200ng/ml; 300ng/ml) Temazepam (200ng/ml; 300ng/ml)</p> <p>Cannabinoids; Cannabinol (20ng/ml; 25ng/ml; 50ng/ml) THC (20ng/ml; 25ng/ml; 50ng/ml) THCC (20ng/ml; 25ng/ml; 50ng/ml)</p> <p>Cocainics; Benzoylecgonine (300ng/ml; 150ng/ml) Cocaethylene (300ng/ml; 150ng/ml) Cocaine (300ng/ml; 150ng/ml)</p> | Method 9.01574 using AB Sciex Triple TOF with fast chromatography | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|---------------------------------|--|---|---------------|
| BODY FLUIDS AND PLASMA (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-house Method | |
| Urine (unpreserved) (cont'd) | <p>Presumptive screening for the presence of the following drugs (cut-off limits) (cont'd):</p> <p>Opiates; Codeine (300ng/ml; 2000ng/ml) DHC (300ng/ml; 2000ng/ml) Morphine (300ng/ml; 2000ng/ml) 6-MAM (10ng/ml)</p> <p>Opioids; Buprenorphine (5ng/ml) EDDP (100ng/ml) Fentanyl (5ng/ml) Methadone (300ng/ml) Norpropoxyphene (300ng/ml) o-desmethyltramadol (300ng/ml) Oxycodone (300ng/ml) Oxymorphone Propoxyphene (300ng/ml) Tramadol (300ng/ml)</p> <p>Psychoactives; Amitriptyline (500ng/ml) Dihydronorketamine Gabapentin (1000ng/ml) Ketamine (500ng/ml; 1000ng/ml) Methaqualone (300ng/ml) Mirtazapine (300ng/ml) Norketamine (500ng/ml; 1000ng/ml) PCP (25ng/ml) Pregabalin (500ng/ml) Quetiapine (300ng/ml)</p> <p>Cathinones; Cathinone Mephedrone (300ng/ml)</p> | Method 9.01574 using AB Sciex Triple TOF with fast chromatography | A |



2144
Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd
Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|---------------------------------|---|--|---------------|
| BODY FLUIDS AND PLASMA (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-house Method | |
| Urine (unpreserved) | Determination of: Ethyl Alcohol | Method 9.0108 using Roche Cobas e501 | A |
| | Creatinine (0.3-50mmol/L) | Method 9.0117 using Roche Cobas e501 | A |
| | Adulteration analysis for: pH | Method 9.0119 using Roche Cobas e501 | A |
| | Specific Gravity | Method 9.0119 using Roche Cobas e501 | A |
| | Oxidants (20-300mg/L) | Method 9.0119 using Roche Cobas e501 | A |
| | Chromates (50-1000mg/L) | Method 9.0119 using Roche Cobas e501 | A |
| | Nitrites (125-1000mg/L) | Method 9.0119 using Roche Cobas e501 | A |
| Urine (Unpreserved) | Confirmation (above specified cut-off limit) of the following drugs (cut-off limits): Amphetamine (200ng/ml) Benzoyllecgonine (100ng/ml; 150ng/ml) 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (100ng/ml; 250ng/ml) 3,4-Methylenedioxyamphetamine (MDA) (200ng/ml) 3,4-Methylenedioxy-N-ethylamphetamine(MDEA) (200ng/ml) 3,4-methylenedioxymethamphetamine (MDMA) (200ng/ml) Methadone (250ng/ml) Methamphetamine (200ng/ml) | Method 12.0263 using solid phase extraction and LCMSMS | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|----------------------------------|--|---|---------------|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-House Methods using | |
| Urine (Unpreserved) (cont'd) | Confirmation (above specified cut-off limit) of the following drugs (cut-off limits): (cont'd) Barbiturates: Amylobarbital Butobarbital Pentobarbital Phenobarbital (200ng/ml) Secobarbital (300ng/ml) | Method 12.0273 using Solid Phase extraction followed by LCMSMS | A |
| | Benzodiazepines: 7 amino nitrazepam (100ng/ml) 7 amino flunitrazepam (10ng/ml) Desmethyl Diazepam (100ng/ml) Diazepam (10ng/ml) Flunitrazepam (10ng/ml) Oxazepam (100ng/ml) Temazepam (100ng/ml) | Method 12.0265 using hydrolysis followed by solid phase extraction and LCMSMS | A |
| | Buprenorphine (2.5ng/ml; 5ng/ml) Norbuprenorphine(2.5ng/ml; 5ng/ml) | Method 12.0270 using hydrolysis and solid Phase extraction followed by LCMSMS | A |
| | Ketamine, (200ng/ml) Norketamine (200ng/ml) | Method 12.0269 using Solid Phase extraction followed by LCMSMS | A |
| | 6-Mono-Acetyl Morphine (10ng/ml) | Method 12.0264 using Solid Phase extraction followed by LCMSMS | A |



2144
Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd
Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|----------------------------------|---|--|---------------|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-House Methods using | |
| Urine (Unpreserved) (cont'd) | Confirmation (above specified cut-off limit) of the following drugs (cut-off limits): (cont'd) Opiates: Morphine (300ng/ml; 2000ng/ml) Codeine (300ng/ml; 2000ng/ml) Dihydrocodeine (300ng/ml; 2000ng/ml) Desmethylpapaverine (5ng/ml) Dihydromorphine (100ng/ml) Hydrocodone (500ng/ml) Noscapine (5ng/ml) Papaverine (5ng/ml) Pholcodine (100ng/ml) Thebaine (5ng/ml) | Method 12.0262 using hydrolysis followed by solid phase extraction, and LCMSMS | A |
| Urine (Unpreserved) | 11-Nor Δ^9 -Tetrahydro Cannabinol-9-Carboxylic Acid (15ng/ml) | Method 12.0261 using hydrolysis followed by solid phase extraction, and LCMSMS | A |
| | Quantitative analysis of the following drugs (concentration range): Amphetamine (25-1000ng/ml) Benzoylcegonine (25-1000ng/ml) 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (25-1000ng/ml) 3,4-Methylenedioxyamphetamine (MDA) ((25-1000ng/ml) 3,4-Methylenedioxy-N-ethylamphetamine(MDEA) (25-1000ng/ml) 3,4-methylenedioxymethamphetamine (MDMA) (25-1000ng/ml) Methadone (25-1000ng/ml) Methamphetamine (25-1000ng/ml) | Method 12.0263 using solid phase extraction and LCMSMS | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|----------------------------------|---|--|--|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-House Methods using | |
| Urine (Unpreserved) (cont'd) | Quantitative analysis of the following drugs (concentration range): (cont'd) Barbiturates: Amylobarbital (25-1000ng/ml) Butobarbital (25-1000ng/ml) Pentobarbital (25-1000ng/ml) Phenobarbital (100-1000ng/ml) Secobarbital (25-1000ng/ml) Benzodiazepines: 7 amino nitrazepam (25-1000ng/ml) 7 amino flunitrazepam (2.5-100ng/ml) Desmethyl Diazepam (25-1000ng/ml) Diazepam (2.5-10ng/ml) Flunitrazepam (2.5-100ng/ml) Oxazepam (25-1000ng/ml) Temazepam (25-1000ng/ml) Buprenorphine (0.5-20ng/ml) Norbuprenorphine (0.5-20ng/ml) Ketamine, (25-1000ng/ml) Norketamine (25-1000ng/ml) 6-Mono-Acetyl Morphine (0.5-20ng/ml) Opiates: Morphine (50-10000ng/ml) Codeine (50-10000ng/ml) Dihydrocodeine (50-10000ng/ml) 11-Nor Δ^9 -Tetrahydro Cannabinol-9-Carboxylic Acid (5-100ng/ml) | Method 12.0273 using Solid Phase extraction followed by LCMSMS Method 12.0265 using hydrolysis followed by solid phase extraction and LCMSMS Method 12.0270 using hydrolysis and solid Phase extraction followed by LCMSMS Method 12.0269 using Solid Phase extraction followed by LCMSMS Method 12.0264 using Solid Phase extraction followed by LCMSMS Method 12.0262 using hydrolysis followed by solid phase extraction, and LCMSMS Method 12.0261 using hydrolysis followed by solid phase extraction, and LCMSMS | A A A A A A |



2144
Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation
issued by
United Kingdom Accreditation Service
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd
Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|--|--|---|---------------|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-House Methods using | |
| Urine (Unpreserved) (cont'd) | Quantitative analysis of the following drugs (concentration range): (cont'd) S-Phenyl Mercapturic Acid (SPMA) (0.5-100ng/MI) | Method 12.0303 by sample dilution and LC-MS-MS | A |
| Oral fluid (extracted from Quantisal collection kit) | Confirmation (above specified cut-off limit) of the following drugs (cut-off limit): Amphetamines: Amphetamine(30ng/mL), Methamphetamine (30ng/mL), MDMA (30ng/mL), MDEA (30ng/mL) Benzodiazepines: Alprazolam, (10ng/mL), Desmethyldiazepam, (10ng/mL), Diazepam, (10ng/mL), Flunitrazepam, (10ng/mL), Lorazepam, (10ng/mL), Oxazepam, (10ng/mL), Temazepam. (10ng/mL) Cocainics: Cocaine, (8ng/mL), Benzoylecgonine, (8ng/mL), Cocaethylene. (8ng/mL) Opiates: Codeine, (40ng/mL), Dihydrocodeine, (40ng/mL), 6Monoacetyl morphine, (4ng/mL), Morphine. (40ng/mL) Synthetic Opioids: Methadone, (20ng/mL) EDDP. (20ng/mL) | Method 12.0271 using sample dilution in buffer and LC-MS-MS | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|---|---|---|---------------|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-House Methods using | |
| Oral fluid (extracted from Quantisal collection kit) (cont'd) | Confirmation (above specified cut-off limit) of the following drugs (cut-off limit): (cont'd) Other psychoactive substances; Ketamine, (30ng/mL), Norketamine. (30ng/mL), Mephedrone (30ng/mL), Propoxyphene, (40ng/mL), Norpropoxyphene. (40ng/mL), Tramadol(40ng/mL) | Method 12.0271 using sample dilution in buffer and LC-MS-MS | A |
| | Quantitative analysis of the following drugs (concentration range): Amphetamines: Amphetamine(4-400ng/mL), Methamphetamine(20-400ng/mL) MDMA (4-400ng/mL), MDEA (20-400ng/mL),. Benzodiazepines: Alprazolam, (4-20ng/mL), Desmethyldiazepam, (8.5-20ng/mL), Diazepam, (10-20ng/mL), Flunitrazepam, (4-20ng/mL), Lorazepam, (4-20ng/mL), Oxazepam, (8-20ng/mL), Temazepam. (9-20ng/mL), Cocainics: Cocaine, (10-400ng/mL), Benzoylecgonine, (4-80ng/mL), Cocaethylene. (5-80ng/mL), | Method 12.0271 using sample dilution in buffer and LC-MS-MS | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|----------------------------------|--|--|---------------|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> Quantitative analysis of the following drugs (concentration range): (cont'd) Opiates: Codeine, (5-400ng/mL), Dihydrocodeine, (4-400ng/mL), 6Monoacetylmorphine, (4-200ng/mL), Morphine. (20-400ng/mL), Synthetic Opioids: Methadone, (4.4-80ng/mL) EDDP. (10-80ng/mL) Other psychoactive substances; Ketamine, (20-400ng/mL), Norketamine. (20-400ng/mL), Mephedrone (30ng/mL), Propoxyphene, (2-400ng/mL), Norpropoxyphene. (20-400ng/mL), Tramadol (2-400ng/mL), | Documented In-House Methods using Method 12.0271 using sample dilution in buffer and LC-MS-MS | A |



2144

Accredited to
ISO/IEC 17025:2005

Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Synlab Laboratory Services Ltd

Issue No: 040 Issue date: 28 August 2019

Testing performed by the Organisation at the locations specified

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location Code |
|--|---|--|---------------|
| BODY FLUIDS AND TISSUES (cont'd) | <u>Workplace Drug Analysis/Medical Legal Analysis (cont'd)</u> | Documented In-House Methods using | |
| | <u>Opinion and interpretation</u> | Documented In-house Methods | |
| Drugs of Abuse in Urine and Oral fluid (Quantisal) | Opinion and interpretation; relating to consistency of results with declared medication | Method 10.0602 opinions and interpretation | A |
| - Saliva | <u>Sampling</u> Saliva Collection for subsequent drug of abuse analysis | Method 6.0701 based on European Laboratory Guidelines for Legally Defensible Workplace Drug Testing, Version 1, 2002, using the Quantisal Device | B |
| - Urine | Specimen collection for subsequent drug of abuse analysis | Method 6.0703 based on European Laboratory Guidelines for Legally Defensible Workplace Drug Testing, Version 1, 2002 | B |
| END | | | |